GlassScriptPhysician profile
Eric F Stakebake
NPI 1619215738
$8,044.46
in general payments reported to CMS, 2019-2025
31 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,546 · 2022: $914 · 2023: $868 · 2024: $2,475 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,282 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,281.54 |
| Education | $302.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,547.32 | 2021-2025 | |
| Allergan, INC. | $750.00 | 2021 | |
| Janssen Biotech, INC. | $744.56 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $657.33 | 2021-2025 | Dupixent |
| Ucb, INC. | $564.22 | 2023-2025 | Bimzelx |
| Pfizer INC. | $486.59 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $344.56 | 2023-2025 | |
| Genzyme Corporation | $333.99 | 2021-2025 | |
| Lilly USA, LLC | $323.63 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $308.50 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $269.52 | 2022-2025 | Nemluvio, Aklief |
| Amgen INC. | $218.79 | 2021-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $164.26 | 2021-2025 | Ilumya |
| Arcutis Biotherapeutics, INC. | $131.20 | 2024 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $125.78 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $125.00 | 2022 | |
| Botanix Sb INC | $123.51 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $123.30 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $117.98 | 2025 | Ycanth |
| Leo Pharma INC. | $116.27 | 2023-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.94 | 2021-2025 | Siliq, Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.86 | 2024-2025 | Spevigo |
| Organon LLC | $63.60 | 2025 | Vtama |
| Journey Medical Corporation | $42.01 | 2021 | |
| Incyte Corporation | $39.00 | 2023-2025 | Opzelura |
| Organogenesis INC. | $31.96 | 2023 | Puraply |
| Genentech USA, INC. | $31.28 | 2021-2024 | Erivedge |
| Fresenius Kabi USA, LLC | $26.79 | 2024 | Idacio |
| Alnylam Pharmaceuticals INC. | $21.55 | 2021 | |
| Biofrontera INC. | $18.46 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Kyowa Kirin, INC. | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Stakebake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.